Navigation Links
Cardium Announces Appointment of Paul A. Foster, M.D. to Lead Generx and Excellarate Late-Stage Development Activities
Date:7/28/2008

SAN DIEGO, July 28 /PRNewswire-FirstCall/ -- Cardium Therapeutics (Amex: CXM) announced the appointment of Paul A. Foster, M.D. as Chief Medical Officer to lead the Company's late-stage clinical development activities at Cardium's Tissue Repair Company for the MATRIX Phase 2b clinical study that is evaluating its Excellarate product candidate for the treatment of diabetic ulcers, and the AWARE Phase 3 clinical study that is evaluating its Generx product candidate as a potential treatment for recurrent myocardial ischemia. Dr. Foster, who is currently Cardium's Vice President and Medical Officer, will assume study oversight responsibilities for both Cardium's and the Tissue Repair Company's clinical programs. Dr. Robert Engler, the Company's Chief Medical Advisor who has been involved in the Generx trials since their inception, will continue to play an active role in those studies, and Dr. Randall Moreadith will continue to focus on evaluating potential new business development and medical device opportunities for the Company.

(Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)

"We are very pleased to have Paul head up development of our key product candidates as they move through late-stage clinical trials," stated Christopher J. Reinhard, Chief Executive Officer and Chairman of Cardium Therapeutics. "Paul's leadership and extensive clinical experience will greatly assist us as we advance our Generx candidate now in Phase 3, and Tissue Repair's Excellarate candidate, which is expected to complete its key Phase 2 study this year."

Dr. Foster was previously Chief Medical Officer and Vice President of Clinical Development and
'/>"/>

SOURCE Cardium Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
2. Cardiums Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014 Provectus Biopharmaceuticals, ... therapies. PV-10, its novel investigational drug for cancer, is ... for systemic side effects. Its oncology focus is on ... has completed phase 2 trials of PV-10 as a ... topical treatment for atopic dermatitis and psoriasis. ...
(Date:10/22/2014)... JOLLA, Calif. , Oct. 22, 2014 ... RGLS ), a biopharmaceutical company leading the ... microRNAs, today announced that it has demonstrated ... an ongoing clinical study evaluating RG-101, a ... the treatment of hepatitis C virus infection ...
(Date:10/20/2014)... 20 de octubre de 2014  PneumRx, Inc. ... de la pulmonología intervencional, anunció hoy la conclusión ... 3 meses antes de lo programado. El Estudio Clínico ... dispositivo de investigación (IDE) aprobada por la FDA ... de espiral de reducción de volumen pulmonar PneumRx ...
Breaking Medicine Technology:Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3
... of the world,s leading research and advisory firms for ... launched the Analogue Tool, a dynamic, interactive web-based platform ... on a range of metrics. The Analogue Tool categorizes ... users to quickly understand market opportunities and select appropriate ...
... (Nasdaq: ESMC ) today announced results for ... Consolidated product revenue from continued operations for fiscal ... in the prior fiscal year.  The Company experienced an ... units, which increased approximately 7.3% and 2.8%, respectively, offset ...
Cached Medicine Technology:Decision Resources Launches Analogue Tool To Help Pharmaceutical Companies Quickly Assess Market Opportunity 2Escalon® Reports Fiscal 2010 Results 2Escalon® Reports Fiscal 2010 Results 3Escalon® Reports Fiscal 2010 Results 4Escalon® Reports Fiscal 2010 Results 5Escalon® Reports Fiscal 2010 Results 6Escalon® Reports Fiscal 2010 Results 7
(Date:10/22/2014)... Austin, TX (PRWEB) October 22, 2014 ... Criminal Minds featuring skin diseases both fictional ... Foundation (CEHMDF), a nonprofit organization committed to advocacy ... wondering if CBS will take the opportunity to impart ... disease. , There are many misconceptions about ...
(Date:10/22/2014)... Norton HealthDay Reporter , TUESDAY, ... the three Ebola cases in Dallas. But, mental health specialists ... Americans. President Barack Obama on Friday appointed an Ebola ... has infected two Dallas nurses who cared for a Liberian ... Presbyterian Hospital. But the U.S. cases are miniscule in ...
(Date:10/22/2014)... Hay House is pleased to announce the official release ... (Paperback; $10.82) written by the highly esteemed Tommy Rosen, leader ... is meant to help readers of all kinds end their ... Recovery 2.0 is not the average self-help book, or a ... for what comes next. For many, Alcoholics Anonymous ...
(Date:10/22/2014)... Healthcare professionals who are looking for ... home or on-the-go via laptops, tablets or mobile ... premium Seminar-on-Demand CE courses. The new courses add ... hours of CE course offerings, allowing therapy ... such a diverse library, there’s something for everyone. ...
(Date:10/22/2014)... Richard Carlson, Managing Partner of Blue ... over 25 years experience. Mr. Carlson is a ... related to EDI, B2B Commerce, RFID and Internet/Intranet technology. ... Board member for Pharmaceutical Commerce Magazine and a Gerson ... is a management and technology consulting firm focused solely ...
Breaking Medicine News(10 mins):Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2
... and the Virgin Mary, Paris Hilton has now turned to ... a 100-count thread . ,The socialite has apparently ... her deal with her prison ordeal. ,According to ... she is psychologically still very weak and is holding on ...
... For the first time, an Indian weather station is ... the impact of climate change and provide weather details ... setting up an Integrated Sensor Suite (ISS), a warning ... weather station, at the Chhota Shigri glacier in Himachal ...
... said they could consider closing down a hospital at the ... left to die on the floor of the emergency room. ... by the Los Angeles County department of Health ... and minorities in South Los Angeles. Predictably it has been ...
... Institute for Health and Clinical Excellence (Nice)s suggestion for ... the NHS .,TWENTY thousand people will be condemned to ... decision is implemented, they contended. , ,Both ... all types of wet age-related macular degeneration (AMD), ...
... slowing down in some African countries due to a series ... Bank report as saying . ,According to the ... Kenya, Zimbabwe and urban areas of Ethiopia, Rwanda, Burundi and ... communities are empowered to help themselves with better delivery of ...
... you a doctor, with expertise in anesthetics and obstetrics? You ... ,You can then make a beeline for Temora, a ... Peter Speirs is offering you half a million dollars. ... person, expectant mothers will have to travel an extra 80 kilometres ...
Cached Medicine News:Health News:Indian Weather Station Near Glacier to Study Global Warming 2Health News:Government Mulls Closure of Hospital Where a Woman Died Unattended in ER 2Health News:Government Mulls Closure of Hospital Where a Woman Died Unattended in ER 3Health News:Government Mulls Closure of Hospital Where a Woman Died Unattended in ER 4Health News:UK Suggestion for Restricted Use of Anti-AMD Drugs Draws Flak 2Health News:UK Suggestion for Restricted Use of Anti-AMD Drugs Draws Flak 3Health News:Half a Million Dollars Offered for GPs With Expertise in Anesthetics and Obstetrics 2
... Blood Collection Needle consists of a BD ... safety shield aligned to the bevel-up position. ... Eclipse Blood Collection Needle has its safety ... attach a secondary safety accessory. Immediate, one-handed ...
37°C incubator for DianaGel cards....
ScanGel® Incubator...
... runs up to 12 mini gels under ... gels can be poured 12 at a ... former and Mini-PROTEAN 3 multi-casting chamber, eliminating ... Ready Gel precast gels offer the convenience ...
Medicine Products: